Eplontersen Preserves Health Status in ATTR-CM Trial
Eplontersen failed to achieve its primary endpoint of reducing cardiovascular mortality and recurrent clinical events in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) over 140 weeks, according to data presented at ... Read More